Press releases for investors and media
Stay current on Regeneron news and company updates
Press releases
Regeneron Announces Investor Conference Presentations
Read morePasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
Read moreRegeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Read moreThe Power of Proof in Modern Science
Connor Hill, top winner of Regeneron Science Talent Search 2026, shows how math thinking helps solve complex scientific challenges
Read the storyThe Regeneron Scientific Journey
A deep understanding of human biology guides our path to potential medicines
Learn moreVoices of Generalized Myasthenia Gravis
Learn what life is like with generalized myasthenia gravis (gMG)
Learn moreFrom biologics to genetic medicines, our journey turns
cutting-edge science into transformative medicine,
redefining excellence and efficiency in research and development.
We're guided by our philosophy of
doing well by doing good
We’re dedicated to responsible business practices, integrating the highest standards of integrity into every facet of our operations. Our responsibility strategy addresses the issues that matter most to our business and our stakeholders — because we understand that our actions have a profound impact on the world around us.
Careers at Regeneron
Join the brightest, most passionate innovators in science. Find your next opportunity by applying for jobs and internships at Regeneron today.
Our clinical trials
Our journey of discovery continues as we strive to transform the lives of people with serious diseases. Discover more about our clinical trials or locate a relevant trial near you.


